Markers of sensitivity, dependence and resistance to endocrine therapy for breast cancer

References

• Early Breast Cancer Trialists’ Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet365, 1687–1717 (2005).
   PubMed Web of Science ®Google Scholar
• Jordan VC. Tamoxifen for the treatment of breast cancer. In: Hormone Therapy in Breast and Prostate Cancer I. Jordan VC, Furr BRA (Eds). Humana Press, NJ, USA, 1–13 (2002).
   Google Scholar
• Miller WR. Background and development of aromatase inhibitors. In: Aromatase Inhibitors. BJA Furr (Ed.). Birkhauser Verlag, Basel, Switzerland, 1–21 (2006).
   Google Scholar
• Eiermann W, Paepke S, Appfelstaedt J et al. Letrozole Neo-Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann. Oncol.12(11), 1527–1532 (2001).
   PubMed Web of Science ®Google Scholar
• Smith IE, Dowsett M, Ebbs SR et al. IMPACT Trialists Group. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J. Clin. Oncol.23(22), 5108–5116 (2005).
   PubMed Web of Science ®Google Scholar
• Semiglazov V, Kletsel A, Semiglazov V et al. Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1–2, T3N0–1, T4N0M0). J. Clin. Oncol.23(16S), Abstract 530 (2005).
   Google Scholar
• Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol.21(11), 2101–2109 (2003).
   PubMed Web of Science ®Google Scholar
• Johnston SR, Martin LA, Head J, Smith I, Dowsett M. Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. J. Steroid Biochem. Mol. Biol.95(1–5), 173–181 (2005).
   PubMed Web of Science ®Google Scholar
• Dixon JM. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer. Expert Rev. Anticancer Ther.8(3), 453–463 (2008).
   PubMed Web of Science ®Google Scholar
• Kaufmann M, von Minckwitz G, Bear HD et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann. Oncol.18(12), 1927–1934 (2007).
   PubMed Web of Science ®Google Scholar
• Ma CX, Ellis MJ. Neoadjuvant endocrine therapy for locally advanced breast cancer. Semin. Oncol.33(6), 650–656 (2006).
   PubMed Web of Science ®Google Scholar
• Murray J, Miller WR, Dixon JM. Neoadjuvant endocrine therapy models. Methods Mol. Med.120, 489–502 (2006).
   PubMedGoogle Scholar
• Macaskill EJ, Dixon JM. Neoadjuvant use of endocrine therapy in breast cancer. Breast J.13(3), 243–250 (2007).
   PubMedGoogle Scholar
• Miller WR, Larionov A, Renshaw L et al. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J. Clin. Oncol.27(9), 1382–1387 (2009).
   PubMed Web of Science ®Google Scholar
• Miller WR, Larionov AA, Renshaw L et al. Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet. Genomics10, 813–826 (2007).
   Google Scholar
• Kuerer HM, Newman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicinbased neoadjuvant chemotherapy. J. Clin. Oncol.17(2), 460–469 (1999).
   PubMed Web of Science ®Google Scholar
• Miller WR, Dixon JM, MacFarlane L, Cameron D, Anderson TJ. Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur. J. Cancer39(4), 462–468 (2003).
   PubMedGoogle Scholar
• Miller WR. Clinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancer. J. Steroid Biochem. Mol. Biol.118, 273–277 (2010).
   PubMedGoogle Scholar
• Miller WR, White S, Dixon JM, Murray J, Renshaw L, Anderson TJ. Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br. J. Cancer94(7), 1051–1056 (2006).
   PubMedGoogle Scholar
• Dowsett M, Smith IE, Ebbs SR et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin. Cancer Res.11(2 Pt 2), S951–S958 (2005).
   PubMed Web of Science ®Google Scholar
• Tao Y, Klause A, Vickers A, Bae K, Ellis M. Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials. J. Steroid Biochem. Mol. Biol.95(1–5), 91–95 (2005).
   PubMedGoogle Scholar
• Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J. Clin. Oncol.19(18), 3808–3816 (2001).
   PubMed Web of Science ®Google Scholar
• Miller WR, Larionov A, Renshaw L et al. Aromatase inhibitors – gene discovery. J. Steroid Biochem. Mol. Biol.106(1–5), 130–142 (2007).
   PubMedGoogle Scholar
• Cappelletti V, Gariboldi M, De Cecco L et al. Patterns and changes in gene expression following neo-adjuvant antiestrogen treatment in estrogen receptor-positive breast cancer. Endocr. Relat. Cancer15(2), 439–449 (2008).
   PubMedGoogle Scholar
• Itoh T, Karlsberg K, Kijima I et al. Letrozole, anastrozole and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach. Mol. Cancer Res.3, 203–218 (2005).
   PubMed Web of Science ®Google Scholar
• Elledge RM, Osborne CK. Oestrogen receptors and breast cancer. BMJ314(7098), 1843–1844 (1997).
   PubMed Web of Science ®Google Scholar
• Fuqua SA, Cui Y. Estrogen and progesterone receptor isoforms: clinical significance in breast cancer. Breast Cancer Res. Treat.87(Suppl. 1), 3–10 (2004).
   Google Scholar
• Ellis MJ, Coop A, Singh B et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res.63, 6523–6531 (2003).
   PubMed Web of Science ®Google Scholar
• Mackay A, Urruticoechea A, Dixon JM et al. Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res.9(3), R37 (2007).
   PubMed Web of Science ®Google Scholar
• Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen upregulated and downregulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology144, 4562–4574 (2003).
   PubMed Web of Science ®Google Scholar
• Lin CY, Strom A, Vega VB et al. Discovery of estrogen receptor a target genes and response elements in breast tumor cells. Genome Biol.5, R66 (2004).
   PubMedGoogle Scholar
• Martin LA, Pancholi S, Chan CM et al. The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr. Relat. Cancer12, 1017–1036 (2005).
   PubMed Web of Science ®Google Scholar
• Dressman MA, Walz TM, Lavedan C et al. Genes that co-cluster with estrogen receptor α in microarray analysis of breast biopsies. Pharmacogenomics J.1, 135–141 (2001).
   PubMedGoogle Scholar
• Sutherland RL, Musgrove EA. Cyclins and breast cancer. J. Mammary Gland Biol. Neoplasia9, 95–104 (2004).
   PubMed Web of Science ®Google Scholar
• Miller WR, Larionov A, Anderson TJ, Evans DB, Dixon JM. Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole. Pharmacogenomics J. DOI: 10.1038/tpj.2010.67 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Hurvitz SA, Pietras RJ. Rational management of endocrine resistance in breast cancer.Cancer113, 2385–2397 (2008).
   PubMed Web of Science ®Google Scholar
• Beresford M, Tumur I, Chakrabarti J, Barden J, Rao N, Makris A. A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer. Clin. Oncol.23(3), 209–215 (2010).
   Google Scholar
• Miller WR, Bartlett J, Brodie AM et al. Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist13, 829–837 (2008).
   PubMed Web of Science ®Google Scholar
• Johnston SRD, Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nature Rev. Cancer3, 821–831 (2003).
   PubMed Web of Science ®Google Scholar
• Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nature Rev. Cancer9, 631–664 (2009).
   PubMed Web of Science ®Google Scholar
• Dowsett M. Biology of estrogen-dependent breast cancer. In: Aromatase Inhibitors for the Treatment of Breast Cancer. MJ Ellis (Ed.). CMP Healthcare Media, Oncology Publishing Group, NY, USA, 1–13 (2005).
   Google Scholar
• Ma CX, Sanchez CG, Ellis MJ. Predicting endocrine therapy responsiveness in breast cancer. Oncology23(2), 133–142 (2009).
   PubMed Web of Science ®Google Scholar
• Elledge RM, Green S, Pugh R et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int. J. Cancer89(2), 111–117 (2000).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Houghton J, Iden C et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann. Oncol.17(5), 818–826 (2006).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Ebbs SR, Dixon JM et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer – a study from the IMPACT trialists. J. Clin. Oncol.23(11), 2477–2492 (2005).
   PubMed Web of Science ®Google Scholar
• Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am. J. Clin. Pathol.123(4), 541–546 (2005).
   PubMed Web of Science ®Google Scholar
• Miller WR, Krause A, Larionov A, Evans DB, Anderson TJ, Dixon JM. Genes discriminating between breast cancers responsive or resistant to the aromatase inhibitor, letrozole. Eur. J. Clin. Med. Oncol.2(1), 17–22 (2010).
   Google Scholar
• Miller WR, Larionov A, Anderson TJ et al. Predicting response and resistance to endocrine therapy: profiling patients on aromatase inhibitors. Cancer112(3 Suppl.), 689–694 (2008).
   PubMedGoogle Scholar
• Buyse M, Loi S, van’t Veer L et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst.98, 1183–1192 (2006).
   PubMed Web of Science ®Google Scholar
• Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J. Clin. Oncol.26, 721–728 (2008).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Johnston S, Martin LA et al. Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience. Endocr. Relat. Cancer12(Suppl. 1), S113–S117 (2005).
   Google Scholar
• Geisler J, Lonning PE. Resistance to endocrine therapy of breast cancer: recent advances and tomorrow’s challenges. Clin. Breast Cancer1, 297–308 (2001).
   PubMedGoogle Scholar
• Perey L, Paridaens R, Noble F et al. Fulvestrant as hormonal treatment in postmenopausal women with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitors: update of a Phase II SAKK trial. Breast Cancer Res. Treat.18, S236 (2004).
   Google Scholar
• Johnston S. Fulvestrant and the sequential endocrine cascade for advanced breast cancer. Br. J. Cancer90(Suppl. 1), S15–S18 (2004).
   Google Scholar
• Miller WR. Aromatase inhibitors and breast cancer. Minerva Endocrin.31, 27–46 (2006).
   PubMedGoogle Scholar
• Miller WR. Controversies in Breast Cancer 2008. Breast Cancer Res.10(Suppl. 4), S1 (2008).
   Google Scholar
• Thurlimann B, Paridaens R, Serin D et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimde: a Phase II multicentre multi-national trial. Eur. J. Cancer33, 1767–1773 (1997).
   PubMed Web of Science ®Google Scholar
• Ingle JN. Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer. Breast Cancer Res.10(Suppl. 4), S17 (2008).
   Google Scholar
• Brauch H, Schroth W, Eichelbaum M et al. Clinical relevance of CYP2D6 genetics for tamoxifen response in breast cancer. Breast Care3, 43–50 (2008).
   PubMedGoogle Scholar
• Goetz MP, Knox S K, Suman VJ et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat.101, 113–121 (2007).
   PubMed Web of Science ®Google Scholar
• Lammers LA, Mathijssen RH, van Gelder T et al. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br. J. Cancer103, 765–771 (2010).
   PubMed Web of Science ®Google Scholar
• Lash TL, Lien EA, Sørensen HT, Hamilton-Dutoit S. Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol.10(8), 825–833 (2009).
   PubMed Web of Science ®Google Scholar
• Kadohama N, Yarborough C, Zhou D, Chen S, Osawa Y. Kinetic properties of aromatase mutants Pro308Phe, Asp309Asn, and Asp309Ala and their interactions with aromatase inhibitors. J. Steroid Biochem. Mol. Biol.43, 693–701 (1992).
   PubMed Web of Science ®Google Scholar
• Sourdaine P, Parker MG, Telford J, Miller WR. Analysis of the aromatase cytochrome P450 gene in human breast cancers. J. Mol. Endocrinol.13(3), 331–337 (1994).
   PubMed Web of Science ®Google Scholar
• Wang L, Ellsworth KA, Moon I et al. Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res.70, 319–328 (2010).
   PubMed Web of Science ®Google Scholar
• Pearce ST, Liu H, Jordan VC. Modulation of estrogen receptor α function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12. J. Biol. Chem.278(9), 7630–7638 (2003).
   PubMedGoogle Scholar
• Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J.15, 2174–2183 (1996).
   PubMed Web of Science ®Google Scholar
• Dowsett M, Harper-Wynne C, Boeddinghaus I et al. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res.61, 8452–8458 (2001).
   PubMed Web of Science ®Google Scholar
• Miller WR, Anderson TJ, White S, Evans D, Krause A, Dixon JM. Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience. Endocr. Relat. Cancer12(Suppl. 1), S119–S123 (2005).
   PubMedGoogle Scholar
• Johnston SRD, Martin LA, Head J, Smith I, Dowsett M. Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. J. Steroid Biochem. Mol. Biol.106, 180–186 (2007).
   PubMed Web of Science ®Google Scholar